Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13433554 | 1.00 | CYP3A4 (0.35) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL19069279 | 1.00 | CYP3A4 (0.35) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13433340 | 1.00 | CYP3A4 (0.35) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13433751 | 1.00 | CYP3A4 (0.35) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13460999 | 1.00 | CYP3A4 (0.35) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL19069278 | 0.94 | CYP3A4 (0.38) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13433555 | 0.94 | CYP3A4 (0.38) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL6912271 | 0.94 | CYP3A4 (0.38) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13474444 | 0.94 | CYP3A4 (0.38) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13433344 | 0.94 | CYP3A4 (0.38) | CYP3A4CTSBADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309685-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| WO-2011002807-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009082697-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CYP3A4 275/4885CTSB 34/4885ADRB3 4135/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CYP3A4 275/4885CTSB 34/4885ADRB3 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.